NewsRoom Articles - Page 2 of 249

TuesdaySep 08, 2026 9:00 am

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at…

FridaySep 04, 2026 10:00 am

Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients

A recent study that was conducted on 5,617 people diagnosed with colorectal cancer found that while it was uncommon for these patients to develop brain metastases, those patients that developed brain metastases had overall shorter survival times than other patients that didn’t develop brain metastases linked to their colorectal cancer. Out of the total study population of colorectal cancer patients, 94 (1.7%) had brain metastases that had been confirmed after radiology tests were done. The average age of the patients with brain metastases was 60. Out of those patients with brain metastases, males had a 60.6% share while the others…

FridaySep 04, 2026 9:00 am

From Molecule to Medicine: Onco-Innovations Aligns ONC010 for Clinical Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations has advanced ONC010 across API manufacturing, polymer optimization, analytical development, preclinical characterization and clinical planning as it works toward human evaluation. A 300-gram development batch of ONC010’s active ingredient achieved approximately 99.3% purity, while a newly identified non-tin catalyst could support improved control of impurities in future polymer manufacturing. The company is building an Australian pathway for a potential First-in-Human study while advancing bioanalytical, metabolism, ADME, toxicology, biodistribution and regulatory preparation during the second half of 2026. Cancer therapies built around DNA damage…

ThursdaySep 03, 2026 10:00 am

Administering Immunotherapy Prior to Surgery Improves Brain Cancer Treatment Outcomes

A preclinical study conducted by a joint team from Switzerland has found that treatment outcomes for glioblastoma patients improved considerably if they received immunotherapy before undergoing surgery to remove the tumors, instead of first having the tumors surgically removed and then receiving immunotherapy. The study findings appeared in the Nature Communications journal. The researchers are based at UNIGE (University of Geneva) and HUG (Geneva University Hospitals) and were led by Associate Professor Denis Migliorini, who works at UNIGE. Only a tiny fraction (5%) of glioblastoma patients survive for five or more years even after receiving existing treatments that include surgery, chemotherapy and radiotherapy. The current practice is to surgically remove as much of the brain…

TuesdaySep 01, 2026 10:00 am

Why Many Companies Are Reconsidering Coverage for GLP-1 Drugs

As GLP-1 use has exploded in the U.S., many companies have started discontinuing coverage of these treatments in the health plans they maintain for their employees. This is a trend worth watching, and it warrants a deeper look to understand why it is happening. First off, GLP-1 drugs are medicines like Wegovy and Zepbound that were designed to help in the treatment of type 2 diabetes. Many of these drugs were eventually also approved by the U.S. FDA for use in weight loss, and their use exploded. You would imagine that if these medications are being used by more and…

MondayAug 31, 2026 9:00 am

Earth Science Tech Inc. (ETST) Taps into New Verticals with Zoolzy Acquisition

Earth Science Tech recently completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products The acquisition delivers value across three growth drivers, including expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market The acquisition represents Earth Science Tech’s move to seize strategic opportunities that broaden the company’s telehealth and pharmacy fulfillment platforms into new, complementary verticals Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Zoolzy LLC. Based in Doral, Florida, where it operates from…

FridayAug 28, 2026 10:00 am

New mRNA Platform May Expedite Delivery of Infectious Disease, Cancer Treatments

mRNA vaccines and therapies have had a profound effect on the way various diseases, including infectious diseases like Covid-19, are treated. Scientists are working to improve how these treatments can be leveraged even more, and a research team has made a discovery that could introduce an improved mRNA platform through which vaccines and other treatments for cancer, infectious diseases and autoimmune conditions can be delivered more efficiently using lower doses than has been the norm. This new study was conducted by a joint team of scientists from Johns Hopkins Medicine, the National Cancer Institute, and Leidos Biomedical Research. The National Institutes of Health (NIH) funded the research. For their…

ThursdayAug 27, 2026 1:30 pm

VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also…

ThursdayAug 27, 2026 12:45 pm

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? Researchers are pursuing that question through…

ThursdayAug 27, 2026 10:00 am

Covid-19 Vaccine Could Extend Survival of Brain Cancer Patients

A recent study has found that patients diagnosed with glioblastoma, a deadly brain cancer, can have extended survival durations if they receive an mRNA Covid-19 shot not more than 100 days before they undergo surgery to remove the tumor. According to the study, patients who got the Covid-19 shot within that timeline prior to undergoing surgery or biopsy were observed to have twice the survival time of patients who didn’t get the shot prior to their biopsy or surgery to remove the glioblastoma tumor. The researchers investigated different vaccines and only found that this beneficial effect was triggered by the…